Biohaven Ltd.

What they do

Biohaven discovers, develops and commercializes therapeutics in immunology, neuroscience and oncology, holding worldwide rights to substantially all of its product candidates. It became an independent public company on October 3, 2022 via spin-off from Biohaven Pharmaceutical Holding Company Ltd. The company has no product revenue; operations consist of clinical trials and preclinical development, including three MoDE/TRAP degraders dosed in Phase 1, opakalim in epilepsy, and taldefgrobep alfa in obesity.

Revenue drivers

• Clinical-stage pipeline (no product revenue) — The company reports no product sales; it funds operations from cash, marketable securities and debt, with losses from operations of $255.3 million in the first half of 2026.
• BHV-1300 MoDE (Graves' disease, rheumatoid arthritis) — Lead extracellular degrader that lowered IgG >80% in Phase 1; pivotal Phase 3 in Graves' disease has been initiated, per the August 2026 earnings release. Any future revenue depends on approval and commercialization.
• BHV-1400 TRAP (IgA nephropathy) — TRAP molecule designed to target Gd-IgA1; a pivotal study in IgAN patients is planned for the second half of 2026. No revenue to date.
• Opakalim (Kv7 ion channel modulation, epilepsy) and taldefgrobep alfa — Opakalim topline Phase 2/3 RISE3 results in focal epilepsy are on track for 2H 2026; enrollment is complete in the Phase 2 taldefgrobep alfa obesity study with topline data expected in 2H 2026.

Recent performance

Net loss was $137.3 million in Q2 2026 and $267.8 million for the six months ended June 30, 2026, versus $198.1 million and $419.8 million in the prior-year periods. Diluted EPS was $(0.91) for Q2 2026 and $(1.80) for the half year. R&D expense fell to $100.8 million in Q2 2026 from $184.4 million a year earlier, and to $204.6 million for the half versus $371.9 million in 2025. As of June 30, 2026, total assets were $370.7 million, total liabilities $358.5 million, shareholders' equity $12.2 million, and cash and equivalents $238.0 million. Operating cash flow was negative $609.4 million for full-year 2025.

Strategy

In Q4 2025 the company initiated portfolio and cost-optimization measures to prioritize three key late-stage programs: Kv7 modulation for epilepsy, MoDE and TRAP extracellular protein degradation for immunological diseases, and myostatin-activin pathway targeting for neuromuscular and metabolic diseases including obesity. It initiated a pivotal Phase 3 study of BHV-1300 in Graves' disease and plans a pivotal Phase 3 study of BHV-1400 in IgAN in 2H 2026. Other pipeline activities include BHV-1530 (FGFR3-directed ADC) with a new clinical supply agreement with Regeneron for combination with cemiplimab, and BHV-1510 (TROP2 ADC) in endometrial cancer.

Risks

• Reliance on a limited number of candidates — The 10-K risk factors state the company depends entirely on the success of a limited number of product candidates, none of which is approved.
• Substantial and recurring losses — Annual net losses from 2021 through 2025 ranged from $213.8 million to $846.4 million, with negative operating cash flow in every year including $609.4 million in 2025.
• Need for additional capital — The 10-K states an inability to raise capital when needed or on favorable terms could force curtailment of planned operations; equity was $12.2 million at June 30, 2026.
• Clinical, regulatory and expense risk — The 10-K notes clinical trials are expensive, time-consuming, involve uncertain outcomes and may not be predictive of future results; pivotal outcomes for BHV-1300, BHV-1400 and opakalim remain pending.

Outlook

Management says pivotal Phase 3 development is underway for BHV-1300 in Graves' disease, with a pivotal Phase 3 study for BHV-1400 in IgAN planned for 2H 2026. Topline results from the Phase 2/3 RISE3 trial of opakalim in focal epilepsy remain on track for 2H 2026. Topline data from the Phase 2 taldefgrobep alfa obesity study are expected in 2H 2026, and new Phase 1 data for BHV-1530 are to be presented at ESMO in October 2026.